Lipid lowering therapy: implications of recent clinical trials

References

• Lloyd-Jones DM , MorrisPB , BallantyneCMet al. 2022 ACC Expert Consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk. J. Am. Coll. Cardiol.80(14), 1366–1418 (2022).
   PubMed Web of Science ®Google Scholar
• Fruchart JC , SantosRD , Aguilar-SalinasCet al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc. Diabetol.18(1), 71 (2019).
   PubMed Web of Science ®Google Scholar
• Saeed A , BallantyneCM. Bempedoic Acid (ETC-1002): a current review. Cardiol. Clin.36(2), 257–264 (2018).
   PubMed Web of Science ®Google Scholar
• Nissen SE , LincoffAM, BrennanDet al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N. Engl. J. Med.388(15), 1353–1364 (2023).
   PubMed Web of Science ®Google Scholar
• Shah ASV , StelzleD , LeeKKet al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation138(11), 1100–1112 (2018).
   PubMed Web of Science ®Google Scholar
• Grinspoon SK , FitchKV , ZanniMVet al. Pitavastatin to prevent cardiovascular disease in HIV infection. N. Engl. J. Med.389(8), 687–699 (2023).
   PubMed Web of Science ®Google Scholar
• Baigent C , BlackwellL , EmbersonJet al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England)376(9753), 1670–1681 (2010).
   PubMed Web of Science ®Google Scholar
• Ridker PM , DanielsonE , FonsecaFAet al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359(21), 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Ridker PM , MacfadyenJG , FonsecaFAet al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ. Cardiovasc. Qual. Outcomes2(6), 616–623 (2009).
   PubMed Web of Science ®Google Scholar
• Ray KK , TroquayRPT , VisserenFLJet al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet. Diabetes Endocrinol.11(2), 109–119 (2023).
   PubMed Web of Science ®Google Scholar
• Oesterle A , LaufsU , LiaoJK. Pleiotropic effects of statins on the cardiovascular system. Circ. Res.120(1), 229–243 (2017).
   PubMed Web of Science ®Google Scholar
• Longo J , Van LeeuwenJE , ElbazM , BranchardE , PennLZ. Statins as anticancer agents in the era of precision medicine. Clin. Cancer Res.26(22), 5791–5800 (2020).
   PubMed Web of Science ®Google Scholar
• Neilan TG , QuinagliaT , OnoueTet al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA Randomized Clinical Trial. JAMA330(6), 528–536 (2023).
   PubMed Web of Science ®Google Scholar
• Gulati G , HeckSL , ReeAHet al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J.37(21), 1671–1680 (2016).
   PubMed Web of Science ®Google Scholar
• Hundley WG , D’agostinoR , CrottsTet al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid.1(9), EVIDoa2200097 (2022).
   Google Scholar
• Kantor ED , RehmCD , DuM , WhiteE , GiovannucciEL. Trends in dietary supplement use among US adults from 1999–2012. JAMA316(14), 1464–1474 (2016).
   PubMed Web of Science ®Google Scholar
• Allen H , LivingHope Productions. Research study reveals black consumer attitudes on treatment for cholesterol. www.prnewswire.com/news-releases/research-study-reveals-black-consumer-attitudes-on-treatment-for-cholesterol-300306856.html
   Google Scholar
• Laffin LJ , BruemmerD , GarciaMet al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J. Am. Coll. Cardiol.81(1), 1–12 (2023).
   PubMed Web of Science ®Google Scholar
• Ito MK . Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis242(2), 647–656 (2015).
   PubMed Web of Science ®Google Scholar
• Das Pradhan A , GlynnRJ , FruchartJCet al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N. Engl. J. Med.387(21), 1923–1934 (2022).
   PubMed Web of Science ®Google Scholar
• Davidson MH , ArmaniA , MckenneyJM , JacobsonTA. Safety considerations with fibrate therapy. Am. J. Cardiol.99(6a), 3c–18c (2007).
   PubMed Web of Science ®Google Scholar
• Kromhout D , BosschieterEB , DeLezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N. Engl. J. Med.312(19), 1205–1209 (1985).
   PubMed Web of Science ®Google Scholar
• Aung T , HalseyJ , KromhoutDet al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol.3(3), 225–233 (2018).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , StegPG , MillerMet al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med.380(1), 11–22 (2019).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ , LincoffAM , GarciaMet al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA324(22), 2268–2280 (2020).
   PubMed Web of Science ®Google Scholar
• Sharma G , MartinSS , BlumenthalRS. Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo?JAMA324(22), 2262–2264 (2020).
   PubMed Web of Science ®Google Scholar
• Budoff MJ , BhattDL , KinningerAet al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur. Heart J.41(40), 3925–3932 (2020).
   PubMed Web of Science ®Google Scholar
• Mason RP , LibbyP , BhattDL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler. Thromb. Vasc. Biol.40(5), 1135–1147 (2020).
   PubMed Web of Science ®Google Scholar
• Tadic M , SalaC , GrassiGet al. Omega-3 fatty acids and coronary artery disease: more questions than answers. J. Clin. Med.10(11), 2495(2021).
   PubMed Web of Science ®Google Scholar
• Bytyçi I , PensonPE , MikhailidisDPet al. Prevalence of statin intolerance: a meta-analysis. Eur. Heart J.43(34), 3213–3223 (2022).
   PubMed Web of Science ®Google Scholar
• Penson PE , BruckertE , MaraisDet al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J. Cachexia Sarcopenia Muscle13(3), 1596–1622 (2022).
   PubMed Web of Science ®Google Scholar
• Wiggins BS , BackesJM , HillemanD. Statin-associated muscle symptoms - a review: individualizing the approach to optimize care. Pharmacotherapy42(5), 428–438 (2022).
   PubMed Web of Science ®Google Scholar
• Wood FA , HowardJP , FinegoldJAet al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N. Engl. J. Med.383(22), 2182–2184 (2020).
   PubMed Web of Science ®Google Scholar
• Herrett E , WilliamsonE , BrackKet al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ372, n135 (2021).
   PubMedGoogle Scholar
• Grundy SM , StoneNJ , BaileyALet al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol.73(24), 3168–3209 (2018).
   PubMed Web of Science ®Google Scholar